SEC Filing Summary: Keros Therapeutics, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Keros Therapeutics, Inc. on January 9, 2026. The filing serves as a Regulation FD disclosure regarding the update of the Company's corporate presentation for use in meetings with investors and analysts. The presentation is attached as Exhibit 99.1.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of a corporate presentation update and does not contain audited financial statements or quarterly results.
Material Changes
No material financial changes or operational events are reported in this filing other than the update to the corporate presentation materials.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained herein, including the attached corporate presentation, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, the information is not incorporated by reference into other filings unless expressly set forth by specific reference. No specific guidance, outlook, or risk factors are detailed within the text of this 8-K.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Corporate Presentation dated January 2026) for detailed business updates, as the 8-K text only references its existence.
- Verify the status of the Company's securities registered on The Nasdaq Stock Market LLC under the symbol KROS.
- Confirm that the presentation materials are not legally incorporated by reference into other SEC filings unless explicitly stated.